Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six month...

The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...

Biocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...

Biocon Biologics is set to integrate a major portion of the biosimilars business acquired from Viatris in the current fiscal year, accordin...

Indian biopharmaceutical company Biocon posted a 31% year-on-year rise in Q4 FY23 net profit, at INR313 crore ($41.9m), driven by successfu...

To fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...

Consolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period, it...

Drugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...

The earnings before interest, tax depreciation and amortisation (EBITDA) rose 25% YoY to Rs 537 crore. The EBITDA margins for the third qua...

The country’s largest biopharmaceutical company’s net profits before exceptional items grew by 11% to Rs 188 crore in the quarter, it repor...

Biologics is the segment to watch as we have invested in it and it is delivering for us.

Biocon reported a 64 per cent jump in its net profit for the quarter ending March 2019.

At the end of 2015, 70% of analysts tracking the Biocon stock had a buy recommendation on it. Data from Bloomberg show that this number has...

Total revenue of the company rose to Rs 952 crore for the first quarter, as compared to Rs 857 crore during the same period of correspondin...

The consolidated revenue of Biocon was up by 11.38 per cent at Rs 861 crore during the quarter compared to Rs 773 crore in the year-ago per...

After the divestment of Axicorp and the snapping of its biosimilar insulin deal with Pfizer, the company was expected to post a subdued per...

With the snapping of ties, the Indian biotech company has limited options for growth of its insulin especially in regulated markets.